证券代码：600488 证券简称：津药药业 编号：2026-014 津药药业股份有限公司 关于股票交易风险提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 2026 年 3 月 26 日至 3 月 31 日期间，公司股票价格累计涨幅 32.32%，鉴于公司股票短期内多次涨停，但公司基本面未发生重大变 化，公司股价可能存在市场情绪过热、非理性炒作情形。公司郑重提 醒广大投资者，公司股价在短期内较大涨幅后可能存在大幅下跌的风 险，请投资者务必充分了解二级市场交易风险，切实提高风险意识， 理性决策，审慎投资。 公司 2025 年前三季度实现营业收入 22.32 亿元，同比下降 13.24%，归属于上市公司股东的净利润 6,953.99 万元，同比下降 62.75%，归属于上市公司股东的扣除非经常性损益的净利润 1.36 亿 元，同比下降 26.06%。公司将于 2026 年 4 月 25 日披露《2025 年年 度报告》，具体的财务数据以公司正式披露的经审计后的《2025 年 年度报告》为准。 公司股票价格 ...

Market Overview - The A-share market showed a strong rebound today, with the Shanghai Composite Index rising by 0.24%, while Japanese and Korean markets fell by nearly 3% each, indicating a competitive advantage for China [1] - The total market turnover reached 19,277.83 billion yuan, an increase of 637.87 billion yuan compared to the previous day, with over 2,800 stocks rising [21] Sector Performance - The aluminum sector led the gains, with companies like Tianshan Aluminum and Chang Aluminum hitting the daily limit. This surge is attributed to attacks on two Middle Eastern aluminum producers, which disrupted global aluminum supply chains [21][31] - The pharmaceutical sector continued to perform well, with stocks like Meinuo Pharma achieving five consecutive limits. The first quarter saw China's innovative drug licensing transactions exceed $60 billion, nearing half of last year's total [21] - The aerospace sector also saw increased activity, with companies like Shenjian Co. and Zengsheng Technology experiencing multiple limit-ups due to recent contract wins and upcoming launches [21] Company Updates - Maiwei Co. experienced a significant drop in stock price, attributed to market rumors regarding export restrictions on equipment and weak first-quarter performance expectations. However, the company has completed the first phase of equipment delivery for HJT production lines in the U.S. [16][18] - The optical fiber sector showed strong performance, with companies like Hengtong Optic-Electric and Changfei Optic-Fiber seeing stock price increases due to rising prices from operators and strong demand from data centers [19][23] - The agricultural sector also saw gains, driven by rising energy prices impacting fertilizer and logistics costs, which in turn raised expectations for agricultural product prices [23] Financial Performance - Zhaoyan New Drug reported a revenue of 1.658 billion yuan for 2025, a decrease of 17.87% year-on-year, but a net profit increase of 302.08% to 298 million yuan [27] - New Sharp Co. expects first-quarter revenue for 2026 to be between 1 billion and 1.15 billion yuan, a year-on-year increase of 89.28% to 117.68% [27] - Huazhi Precision anticipates a first-quarter net profit of 150 to 190 million yuan for 2026, reflecting a year-on-year growth of 413.28% to 550.15% [27] Industry Insights - Goldman Sachs has downgraded the target for the MSCI China Index and the CSI 300 Index by 5% and 4%, respectively, indicating a potential price return of 24% and 12% over the next 12 months [12] - The global economic backdrop is expected to lower the fair value of Chinese stocks by approximately 5%, with 2% attributed to profit deterioration and 3-4% due to a decline in the price-to-earnings ratio [11]

证券代码：600488 证券简称：津药药业 编号：2026-013 津药药业股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 津药药业股份有限公司（以下简称"公司"）股票于 2026 年 3 月 26 日、3 月 27 日、3 月 30 日连续三个交易日内日收盘价格涨幅偏 离值累计达到 20%，根据《上海证券交易所交易规则》的有关规定， 属于股票交易异常波动情形。 经公司自查并向公司控股股东天津药业集团有限公司（以下简 称"药业集团"）、间接控股股东津沪深生物医药科技有限公司（以 下简称"津沪深医药"）书面函询核实，截至本公告披露日，公司及 控股股东不存在应披露而未披露的重大事项。 敬请广大投资者注意二级市场交易风险，理性决策，审慎投资。 一、股票交易异常波动的具体情况 公司股票交易于 2026 年 3 月 26 日、3 月 27 日、3 月 30 日连续 三个交易日内日收盘价格涨幅偏离值累计达到 20%，根据《上海证券 交易所交易规则》的有关规定，属于股票交易异常波动情形。 ...

证券代码：600488 证券简称：津药药业 编号：2026-012 津药药业股份有限公司 为实现公司高质量发展，根据公司发展战略及业务发展需要，公 司对组织机构进行调整如下：质量管理部、药物警戒部、EHS 部并入 供应链管理部，作为二级部门管理；财务中心更名为财经中心，撤销 资产与投资管理部，原资产与投资管理部职能划入财经中心；撤销商 务发展部，职能并入创新研究院；原料药制造中心更名为原料药中心； 撤销营销管理中心，将原料药销售业务划入原料药中心管理。 第九届董事会第二十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 津药药业股份有限公司（以下简称"公司"）第九届董事会第二 十五次会议于 2026 年 3 月 24 日以通讯表决的方式召开。本次会议的 通知已于 2026 年 3 月 19 日以电子邮件的方式送达公司各位董事和高 管人员。会议应参加表决董事 9 人，实际表决董事 9 人，会议由公司 董事长主持，公司高管人员列席了会议。会议符合《公司法》和《公 司章程》的有关规定，决议如下： 1.审议通过关于津药 ...

证券代码：600488 证券简称：津药药业 编号：2026-011 （一）基本信息 签字注册会计师：张尧先生，自 2016 年加入中审华并开始从事 上市公司审计及与资本市场相关的专业服务工作，2022 年 5 月成为 中国注册会计师，现为中国注册会计师执业会员。张尧先生于 2021 津药药业股份有限公司 关于变更签字注册会计师的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 津药药业股份有限公司（以下简称"公司"）分别于 2025 年 3 月 25 日召开第九届董事会第十五次会议、2025 年 4 月 16 日召开 2024 年年度股东大会，审议通过了《关于续聘会计师事务所的议案》，同 意续聘中审华会计师事务所（特殊普通合伙）（以下简称"中审华"） 为公司 2025 年度财务审计和内控审计机构。 近日，公司收到中审华《关于签字注册会计师变动的告知函》， 现将具体情况公告如下： 一、签字注册会计师变更情况 中审华作为公司 2025 年度财务审计和内控审计机构，原指派张 学兵为项目合伙人，李媛为签字注册会计师，董虹彦为项目质 ...

Core Viewpoint - The company is actively addressing regulatory concerns raised by the China Securities Regulatory Commission (CSRC) through comprehensive reforms and a commitment to long-term compliance and risk management [1][2][4]. Group 1: Regulatory Response and Reform - The company has initiated a thorough review and rectification process in response to issues identified by the CSRC, emphasizing principles such as "fact-based assessment" and "long-term control" [1]. - A specialized meeting was convened by the chairman to analyze risks associated with research contracts and to establish clear responsibilities for rectification [2]. - The company has already recovered all advance payments related to terminated research projects due to issues with technology transfer [1]. Group 2: Contract and Project Management Improvements - The company is revising and enhancing its contract templates and audit processes to ensure compliance and establish a long-term rectification mechanism [2]. - A comprehensive risk management framework for research projects has been developed, including the hiring of external consultants to guide the transformation of the research system [2]. - The company has completed major rectification tasks, including the optimization of contract review processes and the establishment of a risk control mechanism for research projects [2]. Group 3: Long-term Compliance and Training Initiatives - The company is building a long-term compliance management system to ensure strict operational standards and a shift towards proactive risk management [3]. - A series of targeted training sessions have been conducted to enhance compliance awareness among employees, covering areas such as contract management and risk prevention [3]. - The company aims to transform compliance and internal control into a value driver, enhancing operational quality and market competitiveness in a stricter regulatory environment [4].

Core Viewpoint - Tianjin Pharmaceutical Co., Ltd. (referred to as "the company") has disclosed a regulatory rectification report addressing previous violations identified by the Tianjin Securities Regulatory Bureau, including internal control deficiencies and the issuance of warning letters to five executives [1][2]. Regulatory Issues - The company faced two main violations: unclear contractual obligations in external technology projects and failure to identify risks in research projects, leading to delays in recovering advance payments. These actions violated the "Corporate Governance Guidelines for Listed Companies" and "Guidelines for Internal Control Applications" [2]. - In response, the company established a special rectification working group to implement corrective measures, including revising contract management processes and enhancing risk control mechanisms for research projects [2][3]. Financial Performance - In 2024, the company reported revenue of 3.215 billion yuan, a 15.0% decrease year-on-year, while net profit increased by 14.01% to 133 million yuan, primarily due to a significant reduction in sales expenses [6]. - Sales expenses dropped dramatically by 45.76% to 570 million yuan, with promotional activity costs falling by 54.23% and market planning service fees decreasing by 60.03% [6]. - However, in 2025, the company faced increased financial pressure, with revenue for the first three quarters amounting to 2.232 billion yuan, a 13.24% decline, and net profit down 62.75% to approximately 69.54 million yuan [6][7]. Legal and Compliance Challenges - The company has been penalized multiple times for monopolistic practices, with total fines exceeding 170 million yuan. A notable case involved a price increase of 62.5% for a key product, resulting in a fine of approximately 69.19 million yuan, which accounted for 51.85% of its net profit for 2024 [4][5]. - The cumulative impact of these penalties has significantly affected the company's cash flow and profitability, highlighting the challenges posed by regulatory compliance and market competition [7].

Core Viewpoint - Tianjin Pharmaceutical Industry Co., Ltd. has acknowledged the regulatory issues raised by the Tianjin Securities Regulatory Bureau and has committed to implementing a comprehensive rectification plan to address these concerns and enhance internal controls and compliance awareness [5][15]. Group 1: Meeting and Decision - The 24th meeting of the 9th Board of Directors was held on February 26, 2026, via telecommunication, with all 9 directors participating [1][3]. - The board unanimously approved the rectification report in response to the Tianjin Securities Regulatory Bureau's corrective measures [1][3]. Group 2: Rectification Requirements - The company aims to strictly adhere to relevant regulations, including the "Guidelines for the Governance of Listed Companies" and internal control application guidelines, ensuring thorough investigation and long-term management of identified issues [5][6]. - The rectification goals include resolving issues related to contract management, timely identification of R&D project termination risks, and improving internal control systems [6][15]. Group 3: Main Issues and Rectification Measures - Identified issues include non-standard contract management and delays in recognizing R&D project termination risks, leading to slow recovery of advance payments [7][10]. - Specific rectification measures include revising contract templates to ensure clarity and compliance, enhancing the contract review process, and establishing a risk management mechanism for R&D projects [8][11]. Group 4: Continuous Rectification Plan - The company has developed a continuous rectification plan to reinforce compliance education, enhance internal control systems, and optimize fund management processes [13][14]. - Ongoing training and supervision will be implemented to ensure adherence to regulations and improve governance standards [13][14]. Group 5: Commitment to Rectification - The board and management have expressed a strong commitment to addressing the issues highlighted by the regulatory authority and ensuring that all rectification measures are completed on time and effectively [15].

证券代码：600488 证券简称：津药药业 编号：2026-010 津药药业股份有限公司 关于天津证监局对公司采取责令改正并对相关人员 出具警示函措施的整改报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据天津证监局《关于对津药药业股份有限公司采取责令改正及 对徐华、李书箱、王福军、张杰、杨福祯采取出具警示函措施的决定》 （津证监措施〔2026〕8 号，以下简称"《决定书》"）所指出的津 药药业股份有限公司（以下简称"公司"）相关问题，公司高度重视， 第一时间向董事会、管理层及相关部门进行通报和传达，同时，对《决 定书》指出的问题进行了全面梳理、深刻反思，明确了问题根源及整 改方向。2026 年 2 月 26 日，公司召开了第九届董事会第二十四次会 议，审议通过《关于天津证监局对公司采取责令改正并对相关人员出 具警示函措施的整改报告的议案》，现将公司整改情况公告如下： 一、整改总体要求 1/ 6 完善公司相关内部控制制度及业务流程，强化全员合规意识和风险防 控能力；健全长效监管机制，提升公司治理和规范运作水平，切实保 ...

证券代码：600488 证券简称：津药药业 编号：2026-009 津药药业股份有限公司 津药药业股份有限公司董事会 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2026 年 2 月 26 日 津药药业股份有限公司（以下简称"公司"）第九届董事会第二 十四次会议于 2026 年 2 月 26 日以通讯表决的方式召开。本次会议的 通知已于 2026 年 2 月 24 日以电子邮件的方式送达公司各位董事和高 管人员。会议应参加表决董事 9 人，实际表决董事 9 人，会议由公司 董事长主持，公司高管人员列席了会议。会议符合《公司法》和《公 司章程》的有关规定，决议如下： 1 1.审议通过关于天津证监局对公司采取责令改正并对相关人员 出具警示函措施的整改报告的议案 董事会同意公司出具的整改报告并将认真落实各项整改措施，通 过本次专项整改，彻底解决监管部门指出的问题；完善公司相关内部 控制制度及业务流程，强化全员合规意识和风险防控能力；健全长效 监管机制，提升公司治理和规范运作水平，切实保护公司、股东及全 体利益相关方的合法权益。 ...